4 research outputs found
Cell walls of the dimorphic fungal pathogens Sporothrix schenckii and Sporothrix brasiliensis exhibit bilaminate structures and sloughing of extensive and intact layers
This work was supported by the Fundação Carlos Chagas de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), grants E-26/202.974/2015 and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grants 229755/2013-5, Brazil. LMLB is a senior research fellow of CNPq and Faperj. NG acknowledged support from the Wellcome Trust (Trust (097377, 101873, 200208) and MRC Centre for Medical Mycology (MR/N006364/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer reviewedPublisher PD
The Effect of Longer Development Times on Product Pipeline Management Performance
In the pharmaceutical industry, value is being destroyed through longer product development times. Given that
patent lives are (normally) fixed at 20 years, the double hit of increasing time to market is evident – higher R&D
costs and less time at market before generic competitors are able to be released into the marketplace. The Policy
implications are massive: A huge and permanent shift away from internal R&D towards partnerships, licensing
deals and acquisitions of more innovative biotechnology companies. In this study, we build a system dynamics
model of the product development pipeline for a single company operating in the pharmaceutical market. The
study shows that in the presence of loss of value due to longer lead times, it is more advantageous to: (a) work
faster to reduce the backlog of projects; (b) increase the number of projects started whenever it is possible reduce
complexity in the pipeline; and also (c) the optimal decision on resource allocation is independent of the loss of
value due to longer lead times